Stem cell transplantation could be a rapid and effective way to restore hemoglobin production in individuals with the blood disorder β-thalassaemia.
A new single-cell technology is giving scientists their clearest view yet of immune cell behavior—capturing not just genetic intent, but real-time activity.
Researchers uncovered how cells selectively destroy certain microRNAs — key gene regulators — through a mechanism that requires two RNA signals working together.
A new blood test combined with a standardized questionnaire and artificial intelligence may transform the way leprosy is diagnosed in Brazil.
A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.
UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting multiple cancers, various liver conditions and organ abnormalities simultaneously by analyzing DNA fragments circulating in the bloodstream.
Researchers have demonstrated a new class of low-cost, scalable sensors that can be used to monitor electrical activity in human cerebral organoids. Because electrical signals are key to understanding brain function, this advancement facilitates research into both neurodevelopment and genetic disorders such as Angelman syndrome.
DURHAM, N.C., March 31, 2026 /PRNewswire/ — Baebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A&B/SARS-CoV-2 Test, an ultra-rapid RT-PCR assay on the FINDER platform. This establishes FINDER as the first molecular point-of-care platform with multifunctional capabilities. The compact, automated system delivers PCR-quality results during the patient visit, with positives as early as 15 minutes and negatives in about 20 minutes, giving urgent care centers, emergency departments, clinics, and other decentralized settings the speed, ease of use, and reliability needed for better diagnostic decisions.
Scientists led by Botond Roska at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and collaborators have identified genetic pathways and compounds capable of protecting cone photoreceptors from the degeneration that underlies conditions like age-related macular degeneration.
Now, scientists at UC San Francisco have developed a method to precisely reprogram these cancer-fighting cells directly inside the body, potentially eliminating the manufacturing process, cost, and waiting time that has kept this life-saving therapy out of reach for many patients around the world.